Podcasts about Moderna

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Esta semana falamos do primeiro navio a vapor a atravessar o Atlântico, em 1819, e sobre as reuniões de Cortes em Portugal, entre os séculos XIII e XIX.Sugestões da semana:1. Eve MacDonald - Cartago - O Império que desafiou Roma. Bertrand, 2026.2. Olivier Aranda, Julien Guinand, Caroline Le Mao - Atlas das Guerras: Época Moderna. Guerra & Paz, 2026.-----Obrigado aos patronos do podcast:André Silva, Bruno Figueira, Cláudio Batista, Gustavo Fonseca, Isabel Yglesias de Oliveira, Joana Figueira, NBisme, Oliver Doerfler, Sara Esteves, Sofia Carvalho;Alexandre Carvalho, Andre Oliveira, Carlos Castro, Civiforum, Lda., Cláudia Conceição, Daniel Murta, Domingos Ferreira, Francisco C, Hugo Picciochi, Jorge Filipe, José Beleza, Luís André Agostinho, Miguel Cunha, Patrícia Gomes, Pedro Almada, Pedro Alves, Pedro Ferreira, Rui Roque, Tiago Pereira, Vera Costa;Adriana Vazão, Ana Gonçalves, André Abrantes, António Farelo, António J. R. Neto, Bruno Luis, Carlos Ribeiro, Carlos Ribeiro, Carolina Batista, Catarina Ferreira, Cláudia Brandão, César, Diogo Camoes, Diogo Freitas, Francisco Castro, Fábio Videira Santos, Gn, Goncalo Castro, GusRo, Hugo Palma, Hugo Vieira, Igor Silva, Joao Godinho, Joel José Ginga, Johnniedee, Jorge Manuel, João Barbosa, João Canto, João Carlos Braga Simões, João Diamantino, João Ferreira, João Félix, João Mendes, Liam Brockey, Luis Colaço, lvlheadwrecker, Mafalda Trindade, Marcos, Miguel Brito, Miguel Gama, Miguel Gonçalves Tomé, Miguel Oliveira, Miguel Salgado, Nuno Carvalho, Nuno Esteves, Nuno Moreira, Nuno Silva, Orlando Silva, Parte Cóccix, Paulo Guerreiro, Paulo Ramirez, Paulo Ruivo, Paulo Silva, Pedro Cardoso, Pedro Oliveira, Pedro Sebastião, Ricardo Pinho, Ricardo Santos, Rodrigo Candeias, Rui Magalhães, Rui Rodrigues, Simão, Simão Ribeiro, Thomas Ferreira, Tiago Matias, Tiago Sequeira, Tomás Matos Pires, Vitor Couto, Zé Teixeira.-----Ouve e gosta do podcast?Se quiser apoiar o Falando de História, contribuindo para a sua manutenção, pode fazê-lo via Patreon: https://patreon.com/falandodehistoria-----Música: "Hidden Agenda” de Kevin MacLeod (incompetech.com); Licensed under Creative Commons: By Attribution 4.0 License, http://creativecommons.org/licenses/by/4.0.Edição de Marco António.

This episode of BizNews Daybreak covers the US-Iran preliminary nuclear agreement, an FDA panel's approval of Moderna's new mRNA flu vaccine, and upcoming Fed inflation data threatening further interest rate hikes. Domestically, Lauren Evanthia discusses a proposed South African cabinet reshuffle and John Steenhuisen's political demotion. Finally, we analyze the massive capital drain from SpaceX, OpenAI, and Anthropic listings, Amazon's Prime Day ecosystem strategy, and Dan Dicker's warnings on critical global oil stockpile drawdowns.

Cap

Cap

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- Fundacion vinte Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Episode 2838 - In this wide-ranging Friday episode, Ted and Austin Broer connect ultra-processed food cardiovascular risk research, the FDA's surprise nine-to-zero approval of Moderna's RNA flu shot with only 26% efficacy, a daily multivitamin study showing reduced biological aging, speed limiter mandates coming to American cars by 2030, Apple's price hikes tied to AI data center memory costs, and foundational supplement guidance into a broadcast that delivers both urgent health warnings and sharp institutional accountability.

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this interview I talked with the Senator from Wisconsin, Ron Johnson. We discussed his bombshell report called, Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals. In this report, Senator Johnson and his team reveals that many people within the FDA and HHS, among other governmental organizations, knew that the COVID-19 vaccines were linked to strokes and even death as early as 2021. Senator Johnson's team found conclusive evidence that the United States Government, the majority of American media companies, and the monopolistic Pharmaceutical Companies worked together to suppress the truth about the Vaccines and, in turn, killed thousands of innocent American citizens. For being one of the most significant reports in modern history, you would think that this story would be on the front page of every major news network and newspaper in America – you would be wrong. Senator Johnson sent his own Op-Ed regarding this report to The New York Times, The Wall Street Journal, USA Today, and many other publications and, to nobodies surprise, he was turned down for publication. We think this had something to do with the fact that many, if not all, of these news companies are sponsored by Pfizer or Moderna and would rather keep in good standing with their financiers than tell the American people the truth about what happened during the COVID-19 Pandemic. We, at The Paradox Press, are not beholden to the Medical Mafia and for that reason, we have the ability to tell the truth. I hope you enjoy. BUY DR MARY TALLEY BOWDEN'S BOOK Go subscribe to The Paradox Press now!Follow me on X: https://x.com/andyschmitt99

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über Zweifel am Debasement Trade, die große Biontech-Debatte, und die Hausse des Gebrauchtwagenhändlers Auto1. Außerdem geht es um SpaceX, Moderna, BioNTech, AMD, Arm, Broadcom, Intel, Micron, Apple, Auto1, Kroger, BMW, Volkswagen, Mercedes-Benz, Tesla, BYD, SAIC, Commerzbank, Goldman Sachs. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

A new Wash U Medicine study takes a closer look at an investigational mRNA-based flu vaccine from Moderna that appears to protect against a wide array of influenza strains. KMOX Health Editor Fred Bodimer found out more about that when he talked with one of the authors of the study Wash U Medicine immunologist Dr. Hanover Matz

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über die Angst der Börsenbosse, Snaps möglichen 2200-Dollar-Brillenflop und die Eskalation der Übernahmeschlacht um Deutschlands zweitgrößte Bank. Außerdem geht es um SpaceX, Amazon, Microsoft, Mercedes-Benz Group, Porsche AG, Volkswagen, GEA Group, Deutsche Bank, SFC Energy, Moderna, Yum Brands, Cboe Global Markets, Miami International Holdings, CME Group, Nasdaq, Hyperliquid Strategies, Meta Platforms, Alphabet, Warby Parker, Apple, UniCredit, Goldman Sachs, Infineon, ASML, Siemens, Rolls-Royce, Enel, Schneider Electric, ABB, Iberdrola, Siemens Energy, ASM International, Prysmian, BE Semiconductor Industries, VAT Group, Aixtron, Soitec, SÜSS MicroTec, Siltronic, Legrand, Nexans, NKT, Engie, National Grid, RWE, E.on, SSE, Terna, Elia. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Moderna's mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review.Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics, which hit the market with $625 million in April, outpacing Moderna's 2018 IPO of $600 million. And now we have Parabilis Medicines, which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million.Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech.Genentech also made a big change last week.Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer's disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma's $2.3 billion acquisition of Ajax Therapeutics in April.Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner's National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi's diabetes drug Tzield was greenlit for older kids and teenagers, though it's unclear whether a voucher was associated with the approval. Meanwhile, Disc Medicine's rejected rare disease drug bitopertin appears to be back on track, with the biotech announcing last week that the FDA will allow its current Phase 3 trial to support another regulatory filing.

Esperamos que bendiga tu vida tanto como bendijo la nuestra. Iglesia Cristiana Palabras de Vida.

Liz Gunn speaks with researcher Clare Swinney about alarming preparations underway in New Zealand councils for a potential high pathogenicity avian influenza (HPAI / bird flu) scenario. Swinney details millions of dollars allocated by the Ministry for Primary Industries for planning, including chicken culling and carcass disposal, dairy cattle considerations, PPE stockpiling, water treatment, and emergency communications.The discussion examines the scientific claims, reliance on PCR testing, historical precedents of mass culling overseas, and parallels with previous pandemic responses. Swinney and Gunn question the transparency of these behind-the-scenes meetings and the potential impacts on food supply and public trust.Links:The Auckland HPAI Plan via Clare's article: https://clareswinney.wordpress.com/2026/03/23/nz-insider-warns-covid-blueprint-guiding-bird-flu-pandemic-planning/What's The Latest “Bird Flu” Scare Really About? (Article): https://clareswinney.wordpress.com/2026/02/16/whats-the-latest-bird-flu-scare-really-about/BBC article regarding the mRNA bird flu vaccine trial: https://www.bbc.com/news/articles/cy41z0yj8mjoProf Jemma Geoghegan speaks about avian influenza (video): https://www.youtube.com/watch?v=Q2SLQiKFRx8The paper by David Crowe and Torsten Engelbrecht titled: Avian flu virus H5N1: No proof for existence, pathogenicity, or pandemic potential; non-“H5N1” causation omitted: https://pmc.ncbi.nlm.nih.gov/articles/PMC7173052/Dr Sam Bailey - Taking Away Your Chickens: https://www.youtube.com/watch?v=YsrV8ta8ox4Dr Sam Bailey - Secrets of Influenza: https://www.youtube.com/watch?v=wzGxKTzuDv0Jon Rappoport - The Creation of A False Epidemic: https://solari.com/the-creation-of-a-false-epidemic-with-jon-rappoport/Jon Rappoport on Substack: https://jonrappoport.substack.com/Avian influenza newsletters, fact sheets, science reports, and other resources (MPI): https://www.mpi.govt.nz/biosecurity/pest-and-disease-threats-to-new-zealand/animal-disease-threats-to-new-zealand/high-pathogenicity-avian-influenza/avian-influenza-newsletters-fact-sheets-and-other-resourcesNew Zealand Clinical Research - Current Trials: https://www.nzcr.co.nz/current-trials/More than One Billion NZ dollars to Moderna from US Government for mRNA Bird Flu Vaccine: https://fortune.com/well/article/bird-flu-vaccine-moderna-mrna-pandemic-influenza-immunization/Jon Fleetwood Article - $19.4 Billion Federal Influenza Pandemic Bill Introduced: H.R. 8447: https://jonfleetwood.substack.com/p/194-billion-federal-influenza-pandemicVitamin D Is More Effective Than Flu Vaccine, Study Says,https://articles.mercola.com/sites/articles/archive/2023/12/09/vitamin-d-better-than-flu-vaccine.aspxWHO - Global Influenza Programme: https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virusFollow Clare: https://clareswinney.wordpress.com/Contact Clare: clareswinney@hotmail.comSupport FreeNZ:Substack: https://freenz.substack.com/Locals: https://freenz.locals.comBuy Me A Coffee: www.buymeacoffee.com/supportfreenzKo-fi: https://ko-fi.com/freenzhttps://freenz.carrd.coEmail: freenewzealand[at]protonmail[dot]com for bank account details.Affiliates:Dioxi Care - Chlorine Dioxide based Oral Care, Skin Care & Veterinary & Wound Care: https://frontierpharm.com/?sca_ref=9717384.brQladA5pgSnoot Spray - Chlorine Dioxide based Nasal Cleaner: https://www.snootspray.com/?sca_ref=9667634.AV2NJQvGlTBlock Blue Light - Red Light Glasses, Full Spectrum Lightbulbs & Sleep Tools to optimise your light environment and prioritise your wellbeing: https://www.blockbluelight.co.nz/?ref=FreeNZMediaWide Awake Media - Freedom T-Shirts: https://wideawake.clothing/en-nz?sca_ref=9458851.1aXfjvGDqL

Un descubrimiento reciente ha sorprendido tanto a arqueólogos como a vulcanólogos: una ciudad moderna, completamente enterrada por una erupción volcánica, acaba de ser desenterrada. Edificios, calles y objetos cotidianos permanecen inquietantemente intactos bajo capas de ceniza y piedra. ¿Podría este ser el Pompeya moderno? ¿Qué causó esta catástrofe? En este video, exploramos la historia, los hallazgos científicos y las imágenes inquietantes de una ciudad perdida por el fuego y la ceniza, y lo que nos dice sobre el poder destructivo de los volcanes en la actualidad. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sabemos la responsabilidad que implica traer un hijo al mundo, o tal vez hacerse cargo de una mascota. Por eso las parejas modernas están optando por no tener responsabilidades y gastarse su dinero en viajes y placer. Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In 2011, Stéphane Bancel walked away from the security of leading a 6,000-person diagnostics company to join a startup of about 50 people, built on an idea most scientists had dismissed: that messenger RNA could become medicine. Almost everyone told him not to do it. He gave the bet roughly a five percent chance. Nine years later, that same bet helped the world face a pandemic in 63 days.Stéphane Bancel is the Chief Executive Officer of Moderna. Under his leadership the company designed a COVID-19 vaccine on a computer within days of the genetic sequence being posted, delivered the first dose to a human just 63 days later, and scaled from zero manufacturing to a billion doses in twelve months. Today Moderna is building personalized cancer vaccines and using AI to reinvent how medicines are discovered and made.This conversation sits right at the heart of what I believe about leadership. That the chief executive is really the chief energy officer. That the boldest decisions are rarely about appetite for risk, they are about the asymmetry between what you could give the world and what you could actually lose. Stéphane lives both, and he is refreshingly honest about the storms, the doubts and the mistakes along the way.In our conversation, we explore: → The five percent bet: how he weighed an enormous upside against a manageable downside, and why his wife was the only one who said yes → What sailing without GPS taught him about staying calm when the storm hits, and why a storm always passes → The 63-day sprint, and the Sunday phone call that saved the manufacturing of a billion doses → Why he slowed a trial down so it would be a vaccine for the world, not a vaccine for white people → The future he sees: personalized cancer vaccines, the human body mapped in silico, and why he calls chemotherapy tomorrow's barbaric history“I still believe that we have not invented yet our best drug.” Stéphane Bancel, CEO of ModernaIf you have ever faced a decision that everyone around you called too risky, this one is about how to think, and how to stay calm, when you choose to leap anyway.

En este episodio exploramos una pregunta que pocos se atreven a hacer, pero que podría cambiar la manera en que entendemos el éxito, el bienestar y el verdadero empoderamiento.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

"Las ciudades que se respetan a sí mismas no derriban los monumentos arquitectónicos", dice una experta ante la pérdida de edificios emblemáticos de la era soviética.

GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/wam USE Code WAM to save 25% plus free shipping! USE Code WAM50 for 50% off on select items like the #10 cans & MRE packs! Pledge here! Just a dollar a month can help keep us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 EXCLUSIVE replays of hour plus long live shows are available here at $5 a month or more! GET 10% OFF ON SHILAJIT FROM DR. KAUFMAN WHEN YOU USE CODE WAM10 HERE: https://medauthentica.com/discount/WAM10?redirect=/products/authentica-shilajit%3Fsca_ref=10867124.wrNV3jkYSaMg9 HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# Josh Sigurdson reports again on the massively increasing cancer rate epidemic as cases skyrocket. While Pam Bondi and Tulsi Gabbard's husband battle cancer, there are a lot of questions regarding where this massive increase is coming from. While doctors claim they are "baffled" by the across the board increases in cancer rates internationally, it's abundantly clear where much of this epidemic stems from. Still, years after the 2021 explosion, few in mainstream science are willing to acknowledge the obvious connections. Rates by 2050 are set to affect almost everyone in the US and UK. Past senate hearings have shown a massive coverup in origin and the origin is pretty clear to anyone paying attention. Pfizer and Moderna have both acknowledged their part following investigations, yet people still roll their eyes and laugh at the connections to the mass injection campaign. While pathologists and even major government figures come out pointing to major studies, there is very little media attention. Pfizer is coming in with their so-called "solution" claiming that "cancer is the new Covid." When they say this, they mean monetarily. Yes, they actually have boasted about this helping them grow revenue as they attempt to come out with an injection for cancer. We've reported time and time again on real world potential solutions. Perhaps it is time for people to take a second look at these potential solutions and the testimonies that back them. Stay tuned for more from WAM! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2026

As health workers in the Democratic Republic of Congo (DRC) continue to battle an ongoing Ebola outbreak, scientists around the world are racing to develop a vaccine against the strain of the virus that's causing it.Two approved vaccines exist for Ebola, but they target the Zaire strain of the virus, not the Bundibugyo strain causing the 2026 outbreak, which has so far killed 61 people with 359 confirmed cases in the DRC and neighbouring Uganda.In this episode, we speak to two scientists at the Oxford Vaccine Group at the University of Oxford, Teresa Lambe and Rebecca Makinson, who are developing a vaccine candidate for Bundibugyo virus. On June 1, they were among three research groups to receive fast-track funding from the Coalition for Epidemic Preparedness Innovations, alongside Moderna and IAVI.This episode was written and produced by Gemma Ware, Katie Flood and Mend Mariwany. Mixing by Eleanor Brezzi and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation.

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Boletín de noticias 04/06/26: Una pareja de ancianos lucha por su vida tras un violento asalto a su domicilio en NSW. Israel y Líbano alcanzan un nuevo acuerdo de alto el fuego. Cuba suspende las transacciones con Visa y Mastercard.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

Send us Fan MailIn this fast-paced episode of Neo News, Eli and Ben tackle the rapidly shifting landscape of vaccine regulation and economics in the US. They discuss recent political maneuvers surrounding the Vaccine Injury Compensation Program (VICP) and how expanding liability could quietly push manufacturers out of the market entirely. The hosts also examine the FDA's recent hesitation to review Moderna's new mRNA flu vaccine, highlighting how these administrative roadblocks threaten the financial viability of developing novel vaccines—including critical immunizations for pediatric and neonatal populations. Tune in for a sharp analysis of how top-down policy changes might reshape everyday clinical practice!----1) https://thehill.com/policy/healthcare/5689850-kennedy-dismisses-vaccine-advisors/2) https://www.washingtonpost.com/opinions/2026/01/15/rfk-jr-vaccines-autism-vicp/3) https://www.nytimes.com/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html4) https://www.nytimes.com/2026/02/16/health/rfk-vaccine-manufacturers.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries.  On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

We mark National Mental Health Awareness Month on this episode by tapping the expertise of Dr. Steve Strakowski, an internationally recognized expert in bipolar disorder, who has spent decades studying the neurobiology and treatment of mood conditions while pushing just as hard on the structural barriers that keep effective treatments out of reach for more than half the people who need them. In this conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Strakowski explains why access, not science, is now the biggest obstacle to improving mental health outcomes. He also addresses the heavy toll society pays for underfunding mental health prevention and treatment programs. “The money is spent eventually, but in the most expensive places like emergency rooms and prisons, and there is the human cost of suffering and suicides." This important discussion also covers: The persistent problem of Black patients presenting with mania being misdiagnosed with schizophrenia;  Why he describes bipolar disorder as a reward-processing illness;  The emerging therapies he finds encouraging. Mentioned in this episode:Indiana University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The media is working overtime to manufacture the next viral panic, and pharma companies are making big money from the fear campaign. After confirming they were already working on a Hantavirus mRNA vaccine before the cruise ship outbreak – and also developing mRNA vax for ebola – Moderna's stock jumped 20%. What an odd coincidence… Diagnostic pathologist Dr. Clare Craig joins Dr. Drew to expose the suspicious timing behind the latest virus hysteria and what the pharmaceutical industry might be planning next – monkeypox, ebola, bird flu, or worse. Eric Bolling breaks down the economic warning signs flashing across the country as diesel prices near all-time highs. CA Lt. Gov. candidate Gloria Romero (running with Steve Hilton) exposes a new plot by California Democrats to repeal the “Top 2” primary system and change the rules of the election to maintain power. Dr. Clare Craig, BM BCh FRCPath, is a Diagnostic Pathologist and author of “Expired: Covid the Untold Story.” She practiced in the NHS for 15 years and became a Fellow of the Royal College of Pathologists. She was the day-to-day pathology lead for the cancer arm of the 100,000 Genomes Project and led R&D at Genomics England. She is Co-Chair of the Health Advisory and Recovery Team (HART Group). Follow at https://x.com/ClareCraigPath Eric Bolling is a TV personality, political commentator, and author. He is the host of TheEDGE and a former co-host of Fox News' The Five. A former commodities trader at the New York Mercantile Exchange specializing in crude oil, gold, and agricultural commodities, he also served on the NYMEX Board of Directors. He is a 2-time NYT bestselling author. Follow at https://x.com/ericbolling Gloria Romero is a candidate for California Lieutenant Governor, running alongside Steve Hilton. A former California State Senate Majority Leader, she was elected to the State Assembly in 1998 and the Senate in 2001. She left the Democratic Party in September 2024 and joined the Republican Party. She is also a professor, educator, and businesswoman. Learn more at https://gloriaromero.com 「 SUPPORT OUR SPONSORS 」 • COVEPURE – Do you know what's in your tap water? Get $250 off your purifier at https://covepure.com/DREW ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

The World Health Organization said 11 hantavirus cases were linked to a cruise ship, including three deaths. However, they also say only 8 of 11 were confirmed cases, and only then by assumptions derived from tests. The three deaths were not caused by the hantavirus. From Johns Hopkins to the CDC, the Hantavirus is described as one of many, with the Andes version being the only one that may be able to spread to humans in rare circumstances. Not only is this likewise unconfirmed, but in the worst case scenario the symptoms are the flu. Of those people on the cruise, the first couple who died were not classified as hanta-cases, and a third sick person had pneumonia which the WHO claims is now caused by Hanta. Meanwhile, there is a federal investigation over a coverup of COVID-19 origins which leads to reinforce the viral contagion narrative. The ship's name Hondius means "dog" and Hanta means "deceive". *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.

In this episode of Bowel Sounds, hosts Dr. Temara Hajjat and Dr. Peter Lu talk to Dr. Maureen Leonard, a pediatric gastroenterologist and Associate Professor at Massachusetts General Hospital. Dr. Leonard discusses the latest research on early life factors that can increase celiac disease risk for susceptible children, including potentially modifiable risk factors. Dr. Leonard's disclosures include:  Consultant for Takeda, Chugai, Anokion, Sonoma, and Interlude Biopharma and research support from Takeda, Pfizer, Regeneron, Moderna, and Mead Johnson Nutrition.Learning objectivesUnderstand early life determinants for celiac diseaseUnderstand environmental influences on developing celiac diseaseSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

As reflexões de Carl von Clausewitz exerceram enorme influência sobre o pensamento militar moderno e continuam presentes nos debates sobre guerra, estratégia e política. Escrevendo em meio às transformações provocadas pelas Guerras Napoleônicas, Clausewitz buscou compreender a natureza dos conflitos armados para além das batalhas em si, formulando conceitos que marcaram profundamente os estudos estratégicos posteriores. Em sua obra mais conhecida, Da Guerra, discutiu temas como a relação entre guerra e política, a fricção, o papel do acaso, a importância da moral das tropas e os limites do planejamento racional em cenários de combate. Seus escritos atravessaram os séculos XIX e XX influenciando militares, governantes e teóricos de diferentes correntes, ao mesmo tempo em que suscitaram interpretações variadas e debates sobre a aplicabilidade de suas ideias em guerras contemporâneas. Convidamos Delmo Arguelhes para analisar os principais conceitos desenvolvidos por Clausewitz, o contexto intelectual e militar em que suas obras foram produzidas e a permanência de seu pensamento nos debates sobre estratégia, política e teoria da guerra.Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iclesrodrigues⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PIX: leituraobrigahistoria@gmail.comAdquira o curso História: da pesquisa à escrita por apenas R$ 49,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso A Operação Historiográfica para Michel de Certeau por apenas R$ 24,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso O ofício do historiador para Marc Bloch por apenas R$ 29,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Colabore com nosso trabalho em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/obrigahistoria⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Versatilidade é com a INSIDER! Meu cupom HISTORIAFM dá 10% de desconto pra cliente recorrente e, até 25/05, dá 30% pra cliente novo! Acesse o site pelo link ⁠⁠⁠https://creators.insiderstore.com.br/HISTORIAFM⁠⁠⁠ e aproveite! #insiderstore

A Dutch couple goes "bird watching" at a landfill in Argentina. Days later, they board a cruise ship — and a Hantavirus outbreak that hadn't surfaced in years suddenly spreads across the passengers. Now Americans from that ship are quarantined in landlocked Nebraska, Moderna's stock has jumped 7.5% on a Hantavirus vaccine they were already developing, and the WHO wants $300 million back from the United States. Does any of this actually add up? Lance Wallnau breaks down the Hantavirus story the mainstream headlines won't touch — what's real, what's suspicious, and what every Christian needs to know before the next pandemic playbook gets rolled out. Bird watching at a landfill? Seriously?   In this episode:   The Argentina landfill detail that government investigators will only speak about anonymously Why Moderna's stock jumped 7.5% on a Hantavirus vaccine BEFORE the outbreak hit headlines The Wuhan wet-market parallel hiding inside the Patagonia origin story Why the WHO wants $300 million back from the U.S. — and why Trump is saying no What Dr. Peter McCullough is recommending Americans keep on hand right now The prophetic prayer over the outbreak — and why Lance believes this one dissipates A Dr. Ben Carson exclusive on the 1963 communist memo that predicted today's headlines America's 250th anniversary, the rededication on the 17th, and why young men are returning to faith in droves   This is the briefing the WHO doesn't want you watching — and the one every believer needs before the next news cycle hits.   Podcast Episode 2118: The Hantavirus 'Bird Watching' Story Nobody Actually Believes | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast  

"When the workforce does not align with the population, your system is misaligned by design." That candid observation comes from Tina Loarte-Rodríguez, DP, RN who has spent much of her two decade career in patient safety, risk management, and systems leadership as the only Latina in the room, which she sees as a signal of a systemic failure that demands structural solutions. As we mark National Nurses Month, Dr. Loarte-Rodríguez joins Raise the Line from Elsevier  host Lindsey Smith to explain why a culturally congruent workforce has important implications for access, trust and quality of care. This wide-ranging discussion also covers: What Dr. Loarte-Rodriguez means by "narrative infrastructure" and how a book series born during COVID is now shaping workforce conversations nationwide;   The case for making mentorship a core institutional system;   Why nursing burnout is not about a lack of resiliency.  Mentioned in this episode: Latinas in NursingThe Connecticut Center for Nursing Workforce If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Propaganda-Palooza: Hantavirus Warm-Up, UFO Thumb Drives, and a Robot Monk Walks Into a Temple McShane and Fitz open Propaganda-Palooza,” by ripping into overlapping narratives: a sudden hantavirus cruise-ship outbreak (plus norovirus headlines), WHO messaging, and renewed “pandemic prep” vibes they refuse to comply with again. The guys argue the fear cycle is timed, point to Moderna vaccine talk, play a 2017 Fauci clip about a “surprise outbreak,” and compare the rollout to an X-Files scene about hantavirus and emergency powers. They also cover a pastor claim that clergy were briefed to prepare congregations for alien disclosure, followed by Fox's Peter Doocey teasing AARO “UFO disclosure” files on a thumb drive, which they frame as distraction. Along the way: exploding beers, barrel-aged stout and barley wine reviews, a satire “SPCS” clip, climate narrative mockery, a discussion on dreaming and brain adaptation, a farm report, and outrage at a South Korean robot monk. We were balls deep this week and we think you're going to like every bit of it.  Download or stream usBecome a supporter of this podcast: https://www.spreaker.com/podcast/razor-wire-news--5683729/support.www.razorwirenews.com

Barbara from Yonkers, NY, shared that she's heard Moderna is supposedly working on a new vaccine for the Hantavirus. Dr. Bob called in, voicing concerns about Republican candidate Bruce Blakeman's campaign style.

Barbara from Yonkers, NY, shared that she's heard Moderna is supposedly working on a new vaccine for the Hantavirus. Dr. Bob called in, voicing concerns about Republican candidate Bruce Blakeman's campaign style.See omnystudio.com/listener for privacy information.

On this, our 325th Evolutionary Lens livestream, we discuss Hanta virus and drought. First: what is the natural history of Hantavirus, do any Hantaviruses transmit directly from human to human, and what is going on with the M.V. Hondius, the cruise ship on which Hantavirus has made a stand? Given its mechanisms of action, Ivermectin is likely to treat Hantavirus (a negative sense single-stranded RNA virus), but the WHO dismisses the possibility. Moderna is working on a Hantavirus vaccine, even though the Number Needed to Treat is sky high. What is going on? Then: in Washington state, we're experiencing a very wet drought. The Department of Ecology has declared a drought (again), and the snow pack is low, but all other indicators—from rivers to reservoirs to soil moisture—are excellent. Cliff Mass, atmospheric scientist, puts the evidence in one place and calls bull on the drought diagnosis.*****Our sponsors:Xlear: Xylitol nasal spray that acts as prophylaxis against respiratory illnesses by reducing the stickiness of bacteria and viruses. Find Xlear online, or at your local pharmacy, grocery store, or natural products store.Fresh Pressed Olive Oil Club: Freshly harvested and delicious. Go to http://www.GetFreshDarkHorse.com to get a bottle of the best olive oil you've ever had for $1 shipping.CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Hantavirus and the elders: https://asm.org/articles/2024/october/indigenous-knowledge-solved-mysterious-outbreakToledo et al 2022. Evidence for human-to-human transmission of hantavirus: a systematic review. The Journal of infectious diseases, 226(8): 1362-1371: https://academic.oup.com/jid/article/226/8/1362/6369311Zaidi & Dehgani-Mobaraki 2022. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. The Journal of antibiotics, 75(2): 60-71: https://www.nature.com/articles/s41429-021-00491-6The WHO on the recent outbreak: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON599Cliff Mass – There is no drought emergency: https://cliffmass.blogspot.com/2026/05/the-is-no-drought-emergency-in.htmlStatewide drought declared in WA: https://ecology.wa.gov/about-us/who-we-are/news/2026/april-8-statewide-drought-declared-due-to-dismal-snowpackSupport the show